A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab

被引:16
|
作者
Miyoshi, Fumihiko [1 ,5 ]
Honne, Kyoko [2 ]
Minota, Seiji [2 ]
Okada, Masato [3 ]
Ogawa, Noriyoshi [4 ]
Mimura, Toshihide [1 ]
机构
[1] Saitama Med Univ, Dept Rheumatol & Appl Immunol, Fac Med, Morohongo 38, Moroyama, Saitama 3500495, Japan
[2] Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi, Japan
[3] St Lukes Int Hosp, Immunorheumatol Ctr, Tokyo, Japan
[4] Hamamatsu Univ Sch Med, Internal Med 3, Div Rheumatol & Immunol, Hamamatsu, Shizuoka, Japan
[5] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Biol Res Labs, Saitama, Japan
关键词
Clinical data; Infliximab; Machine-learning; Rheumatoid arthritis; The prediction of clinical response; MONOCLONAL-ANTIBODY; EXPRESSION PROFILE; BLOOD-CELLS; RESPONSIVENESS; THERAPIES; CANCER;
D O I
10.3109/14397595.2016.1168536
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to generate a novel method for predicting the clinical response to infliximab (IFX), using a machine-learning algorithm with only clinical data obtained before the treatment in rheumatoid arthritis (RA) patients. Methods: We obtained 32 variables out of the clinical data on the patients from two independent hospitals. Next, we selected both clinical parameters and machine-learning algorithms and decided the candidates of prediction method. These candidates were verified by clinical variables on different patients from two other hospitals. Finally, we decided the prediction method to achieve the highest score. Results: The combination of multilayer perceptron algorithm (neural network) and nine clinical parameters shows the best accuracy performance. This method could predict the good or moderate response to IFX with 92% accuracy. The sensitivity of this method was 96.7%, while the specificity was 75%. Conclusions: We have developed a novel method for predicting the clinical response using only background clinical data in RA patients before treatment with IFX. Our method for predicting the response to IFX in RA patients may have advantages over the other previous methods in several points including easy usability, cost-effectiveness and accuracy.
引用
收藏
页码:813 / 816
页数:4
相关论文
共 50 条
  • [31] Predicting pathological response to neoadjuvant chemotherapy in breast cancer patients based on imbalanced clinical data
    Gao, Ting
    Hao, Yaguang
    Zhang, Haipeng
    Hu, Lina
    Li, Hongzhi
    Li, Hui
    Hu, LiHong
    Han, Bing
    PERSONAL AND UBIQUITOUS COMPUTING, 2018, 22 (5-6) : 1039 - 1047
  • [32] Treatment with infliximab is associated with "major clinical response" in psoriatic arthritis patients treated with infliximab: Analysis of two double-blind placebocontrolled trials
    Kavanaugh, Arthur
    Krueger, Gerald G.
    Birbara, Charles
    Halter, Dale
    Geusens, Piet
    de Vlam, Kurt
    Zhou, Bei
    Dooley, L.
    Guzzo, Cynthia
    Bala, M. Ann
    Beutler, Anna
    Antoni, Christian
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1824 - 1824
  • [33] Predicting Anemia in Patients Through Clinical and Hematological Data Using Machine Learning Algorithms
    Meza, Alexis
    Paucar, Kevin
    Morales, Edson
    Ticona, Wilfredo
    SOFTWARE ENGINEERING METHODS DESIGN AND APPLICATION, VOL 1, CSOC 2024, 2024, 1118 : 254 - 266
  • [34] Novel Imputation Method Using Average Code from Autoencoders in Clinical Data
    Macias, Edwar
    Serrano, Javier
    Lopez Vicario, Jose
    Morell, Antoni
    28TH EUROPEAN SIGNAL PROCESSING CONFERENCE (EUSIPCO 2020), 2021, : 1576 - 1579
  • [35] 2-year data: Infliximab maintains clinical response in psoriatic arthritis patients-data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, ZN
    Burmester, G
    Schneider, U
    Furst, DE
    Moliter, J
    Keystone, EC
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, M
    Kalden, JR
    Smolen, JS
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S209 - S209
  • [36] Emulating a Novel Clinical Trial Using Existing Observational Data Predicting Results of the PreVent Study
    Admon, Andrew J.
    Donnelly, John P.
    Casey, Jonathan D.
    Janz, David R.
    Russell, Derek W.
    Joffe, Aaron M.
    Vonderhaar, Derek J.
    Dischert, Kevin M.
    Stempek, Susan B.
    Dargin, James M.
    Rice, Todd W.
    Iwashyna, Theodore J.
    Semler, Matthew W.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2019, 16 (08) : 998 - 1007
  • [37] Emden: A novel method integrating graph and transformer representations for predicting the effect of mutations on clinical drug response
    Liu, Zhe
    Bao, Yihang
    Wang, Weidi
    Pan, Liangwei
    Wang, Han
    Lin, Guan Ning
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 167
  • [38] OBESITY AND RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: POOLED ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM CLINICAL TRIALS
    Singh, Siddharth
    Proudfoot, James
    Xu, Ronghui
    Sandborn, William J.
    GASTROENTEROLOGY, 2018, 154 (01) : S103 - S104
  • [39] The feasibility of predicting cardiotoxicity (cardiac contractility) with high confidence by using clinical only data prior to medicinal chemistry campaigns
    Billson, Jeremy
    Maddock, Helen
    Linekar, Adam
    Hurst, Josh
    Wallis, Rob
    Fletcher, Sophie
    Kidley, Nathan
    Slater, Martin
    Scoffin, Robert
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2022, 117
  • [40] OBESITY AND RESPONSE TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: POOLED ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM CLINICAL TRIALS
    Singh, Siddharth
    Proudfoot, James
    Xu, Ronghui
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S73 - S73